Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Brazil.
Department of Pediatrics, Federal University of Bahia School of Medicine, Salvador, Brazil.
Pediatr Pulmonol. 2018 Jan;53(1):88-94. doi: 10.1002/ppul.23891. Epub 2017 Oct 13.
To assess the role of human bocavirus 1 (HBoV1) as a causative agent of non-severe community-acquired pneumonia (CAP) in children.
Patients aged 2-59 months with non-severe CAP (respiratory complaints and radiographic pulmonary infiltrate/consolidation) attending a University Hospital in Salvador, Brazil were enrolled in a prospective cohort. From 820 recruited children in a clinical trial (ClinicalTrials.gov NCT01200706), nasopharyngeal aspirate (NPA), and acute and convalescent serum samples were obtained from 759 (92.6%) patients. NPAs were tested for 16 respiratory viruses by PCR. Acute HBoV1 infection was confirmed by measuring specific IgM and IgG responses in paired serum samples.
Respiratory viruses were detected in 693 (91.3%; 95%CI: 89.1-93.2) CAP cases by PCR. HBoV1-DNA was detected in 159 (20.9%; 95%CI: 18.2-24.0) cases. Of these 159 PCR positive cases, acute HBoV1 infection was confirmed serologically in 38 cases (23.9%; 95%CI: 17.8-31.0). Overall, acute HBoV1 infection was confirmed in 5.0% (38/759) of non-severe CAP patients. HBoV1 was detected in 151 cases with at least one other virus making 31.7% of all multiple virus (n = 477) detections. Among all 759 cases, 216 had one respiratory virus detected, and sole HBoV1 was detected in only 8 (3.7%). Acute HBoV1 infection was serologically diagnosed in 34 (22.5%) HBoV1-DNA-positive cases with another virus, compared to 4 (50.0%) cases with sole virus detection (p = 0.09).
HBoV1 was detected by PCR in one fifth of the children with non-severe CAP and acute HBoV1 infection was serologically confirmed in one quarter of these cases.
评估人博卡病毒 1 型（HBoV1）作为儿童社区获得性非重症肺炎（CAP）病因的作用。
巴西萨尔瓦多大学医院招募了年龄在 2-59 个月之间患有非重症 CAP（呼吸症状和肺部放射影像浸润/实变）的患儿，进行前瞻性队列研究。在一项临床试验（ClinicalTrials.gov NCT01200706）中，共招募了 820 名患儿，其中 759 名（92.6%）患儿获得了鼻咽抽吸物（NPA）和急性及恢复期血清样本。通过 PCR 检测 NPA 中 16 种呼吸道病毒。通过检测配对血清样本中的特异性 IgM 和 IgG 反应来确定急性 HBoV1 感染。
PCR 检测到 693 例（91.3%；95%CI：89.1-93.2）CAP 病例中有呼吸道病毒。159 例（20.9%；95%CI：18.2-24.0）PCR 阳性病例中检测到 HBoV1-DNA。在这 159 例 PCR 阳性病例中，38 例（23.9%；95%CI：17.8-31.0）经血清学确认为急性 HBoV1 感染。总的来说，5.0%（38/759）非重症 CAP 患儿被确认为急性 HBoV1 感染。在至少检测到一种其他病毒的 151 例病例中，HBoV1 占所有多重病毒（n=477）检测的 31.7%。在所有 759 例病例中，216 例检测到一种呼吸道病毒，仅 8 例（3.7%）检测到单纯 HBoV1。在有其他病毒的 HBoV1-DNA 阳性病例中，34 例（22.5%）经血清学诊断为急性 HBoV1 感染，而在仅检测到病毒的病例中，有 4 例（50.0%）被诊断为急性 HBoV1 感染（p=0.09）。
PCR 检测到 1/5 的非重症 CAP 患儿中存在 HBoV1，其中 1/4 的病例经血清学确认为急性 HBoV1 感染。
